178 related articles for article (PubMed ID: 34340981)
41. Comment on "immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab".
Mungmunpuntipantip R; Wiwanitkit V
Clin Exp Med; 2023 Jul; 23(3):955. PubMed ID: 36053341
[No Abstract] [Full Text] [Related]
42. Recombinant
Kim BJ; Jeong H; Seo H; Lee MH; Shin HM; Kim BJ
Front Immunol; 2021; 12():712274. PubMed ID: 34512635
[TBL] [Abstract][Full Text] [Related]
43. [Immunological research of COVID-19 and emerging infectious diseases].
Cao XT
Zhonghua Yi Xue Za Zhi; 2021 Jan; 101(1):1-6. PubMed ID: 33423443
[TBL] [Abstract][Full Text] [Related]
44. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19.
Mazzoni A; Di Lauria N; Maggi L; Salvati L; Vanni A; Capone M; Lamacchia G; Mantengoli E; Spinicci M; Zammarchi L; Kiros ST; Rocca A; Lagi F; Colao MG; Parronchi P; Scaletti C; Turco L; Liotta F; Rossolini GM; Cosmi L; Bartoloni A; Annunziato F;
J Clin Invest; 2021 Jun; 131(12):. PubMed ID: 33939647
[TBL] [Abstract][Full Text] [Related]
45. Low levels of anti-SARS-CoV-2 antibodies after vaccination in rituximab-treated patients: comment on the article by Simon et al.
Evangelatos G; Kouna K; Fragoulis GE; Moschopoulou M; Triantafylli M; Lekka A; Iliopoulos A
Arthritis Rheumatol; 2022 May; 74(5):908-909. PubMed ID: 34725965
[No Abstract] [Full Text] [Related]
46. [Vaccination immunology in SARS-CoV-2].
Helweg-Larsen J; Benfield T
Ugeskr Laeger; 2021 Mar; 183(11):. PubMed ID: 33734074
[TBL] [Abstract][Full Text] [Related]
47. Comment on: "SARS CoV-2 vaccine AND rituximab, timing is probably a key for a better vaccine response" by Verhoeven et al. Joint Bone Spine 2021;88:105258.
De Marchi G; Fabris M; Domenis R; Curcio F; De Vita S; Quartuccio L
Joint Bone Spine; 2022 Oct; 89(5):105408. PubMed ID: 35577050
[No Abstract] [Full Text] [Related]
48. The level of protective post-vaccination antibodies in NIPH-NIH employees after administration of Pfizer vaccine against COVID-19.
Rastawicki W; Płaza K
Przegl Epidemiol; 2021; 75(1):3-13. PubMed ID: 34328282
[TBL] [Abstract][Full Text] [Related]
49. [SARS-CoV-2 vaccines and reaction of the immune system. Can the epidemic spread of the virus be prevented by vaccination?].
Schmidt J; Blessing F; Gürtler L
Dtsch Med Wochenschr; 2021 Aug; 146(16):1085-1090. PubMed ID: 34416777
[TBL] [Abstract][Full Text] [Related]
50. Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.
Dahiya S; Luetkens T; Lutfi F; Avila S; Iraguha T; Margiotta P; Hankey KG; Lesho P; Law JY; Lee ST; Baddley J; Kocoglu M; Yared JA; Hardy NM; Rapoport AP; Atanackovic D
Blood Adv; 2022 Jan; 6(2):686-689. PubMed ID: 34941995
[No Abstract] [Full Text] [Related]
51. Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.
Ostadgavahi AT; Booth R; Sisson G; McMullen N; Warhuus M; Robertson P; Miller M; Allen WC; El Sherif M; Brownlie R; Falzarano D; Richardson CD
J Infect Dev Ctries; 2021 May; 15(5):653-656. PubMed ID: 34106888
[TBL] [Abstract][Full Text] [Related]
52. Reply to Dushoff et al. and Pifarré i Arolas et al.: Age prioritization for COVID-19 vaccination does save lives and years of life.
Goldstein JR; Cassidy T; Wachter KW
Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34230101
[No Abstract] [Full Text] [Related]
53. Response to comment on "An evidence-based guide to SARS-Cov-2 vaccination of patients on immunotherapies in dermatology.".
Gresham LM; Marzario B; Dutz J; Kirchhof MG
J Am Acad Dermatol; 2021 Aug; 85(2):e91. PubMed ID: 33878412
[No Abstract] [Full Text] [Related]
54. Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'.
Smerilli G; Cipolletta E; Moscioni E; Francioso F; Risa AM; Maccarrone V; Zompa D; Di Matteo A; Di Carlo M; De Angelis R; Salaffi F; Filippucci E; Grassi W
Ann Rheum Dis; 2021 Oct; 80(10):e168. PubMed ID: 33962960
[No Abstract] [Full Text] [Related]
55. Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs'.
Bugatti S; Balduzzi S; De Stefano L; Manzo A; Xoxi B; Bogliolo L; Monti S; Delvino P; Montecucco C
Ann Rheum Dis; 2021 Oct; 80(10):e156. PubMed ID: 33906858
[No Abstract] [Full Text] [Related]
56. Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice.
Turan RD; Tastan C; Dilek Kancagi D; Yurtsever B; Sir Karakus G; Ozer S; Abanuz S; Cakirsoy D; Tumentemur G; Demir S; Seyis U; Kuzay R; Elek M; Kocaoglu ME; Ertop G; Arbak S; Acikel Elmas M; Hemsinlioglu C; Hatirnaz Ng O; Akyoney S; Sahin I; Kayhan CK; Tokat F; Akpinar G; Kasap M; Kocagoz AS; Ozbek U; Telci D; Sahin F; Yalcin K; Ratip S; Ince U; Ovali E
Sci Rep; 2021 Aug; 11(1):15799. PubMed ID: 34349145
[TBL] [Abstract][Full Text] [Related]
57. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!
Guarino M; Cossiga V; Esposito I; Furno A; Morisco F
J Hepatol; 2022 Jan; 76(1):237-239. PubMed ID: 34358567
[No Abstract] [Full Text] [Related]
59. COVID-19 Vaccination and Cancer: Correspondence.
Mungmunpuntipantip R; Wiwanitkit V
Asian Pac J Cancer Prev; 2021 Nov; 22(11):3417. PubMed ID: 34837894
[No Abstract] [Full Text] [Related]
60. [Possible mechanisms of impaired post-vaccination immune response in obesity].
Dzhumagaziev AA; Kostinov MP; Bezrukova DA; Usaeva OV
Vopr Pitan; 2021; 90(5):15-24. PubMed ID: 34719139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
